Physician profile
Jeremy Payne Davis
NPI 1386997351
$35,049.53
in general payments reported to CMS, 2019-2025
24 companies · $19K in 2025
The $19K reported for 2025 was more than what 99% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $713 · 2022: $1,520 · 2023: $1,923 · 2024: $12K · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $15K · Food and Beverage: $10K · Travel and Lodging: $4,521 · Consulting Fee: $3,358.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $14,895.00 |
| Food and Beverage | $10,042.44 |
| Travel and Lodging | $4,521.31 |
| Consulting Fee | $3,358.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $17,678.07 | 2024-2025 | Rezdiffra, Resmetirom |
| Gilead Sciences, INC. | $7,401.01 | 2021-2025 | Livdelzi, Epclusa, Vemlidy |
| Ipsen Biopharmaceuticals, INC | $2,955.12 | 2025 | Iqirvo |
| Mirum Pharmaceuticals, INC. | $1,647.07 | 2025 | Livmarli |
| Abbvie INC. | $1,458.48 | 2021-2025 | |
| Intercept Pharmaceuticals, INC. | $1,020.71 | 2021-2025 | Ocaliva |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $666.85 | 2021-2024 | Xifaxan, Trulance |
| Genzyme Corporation | $581.12 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $492.17 | 2021-2025 | Entyvio, Gattex |
| Ardelyx, INC. | $164.03 | 2023-2024 | Ibsrela |
| Boston Scientific Corporation | $150.00 | 2025 | General - Hemostasis |
| Phathom Pharmaceuticals, INC. | $132.08 | 2025 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $120.39 | 2024 | Zeposia |
| Janssen Biotech, INC. | $120.28 | 2025 | Tremfya |
| Daiichi Sankyo INC. | $87.78 | 2022-2023 | Injectafer |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $86.45 | 2023-2024 | Sucraid, Sucraid |
| Evoke Pharma, INC. | $78.28 | 2021-2024 | |
| Ironwood Pharmaceuticals, INC | $38.81 | 2023-2024 | Linzess |
| Novo Nordisk INC | $37.02 | 2025 | Wegovy |
| Pfizer INC. | $31.32 | 2023-2024 | |
| Lilly USA, LLC | $29.68 | 2024-2025 | Omvoh |
| Fujifilm Healthcare Americas Corporation | $29.61 | 2024 | Utaswako Afp-L3 |
| Glaxosmithkline, LLC. | $27.02 | 2025 | |
| Mallinckrodt Hospital Products INC. | $16.18 | 2025 | Terlivaz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeremy Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.